KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Cash from Operations (2016 - 2026)

Travere Therapeutics filings provide 16 years of Cash from Operations readings, the most recent being 40366000.0 for Q1 2026.

  • On a quarterly basis, Cash from Operations rose 4.33% to 40366000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 39612000.0, a 125.84% increase, with the full-year FY2025 number at 37784000.0, up 116.43% from a year prior.
  • Cash from Operations hit 40366000.0 in Q1 2026 for Travere Therapeutics, down from 60678000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 60678000.0 in Q4 2025 to a low of 118902000.0 in Q1 2024.
  • Median Cash from Operations over the past 5 years was 42507000.0 (2024), compared with a mean of 48165235.29.
  • Biggest five-year swings in Cash from Operations: tumbled 666.59% in 2022 and later skyrocketed 314.65% in 2025.
  • Travere Therapeutics' Cash from Operations stood at 76704000.0 in 2022, then rose by 16.08% to 64373000.0 in 2023, then skyrocketed by 56.09% to 28269000.0 in 2024, then skyrocketed by 314.65% to 60678000.0 in 2025, then plummeted by 166.52% to 40366000.0 in 2026.
  • The last three reported values for Cash from Operations were 40366000.0 (Q1 2026), 60678000.0 (Q4 2025), and 14317000.0 (Q3 2025) per Business Quant data.